Dermira Inc (NASDAQ:DERM) insider Eugene A. Bauer sold 2,500 shares of the business’s stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $33.53, for a total value of $83,825.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Dermira Inc (NASDAQ:DERM) traded down 2.75% on Friday, reaching $32.54. The company had a trading volume of 221,622 shares. The company’s 50 day moving average price is $34.83 and its 200-day moving average price is $32.39. Dermira Inc has a 1-year low of $23.33 and a 1-year high of $38.75. The stock’s market capitalization is $1.16 billion.
Dermira (NASDAQ:DERM) last issued its earnings results on Tuesday, February 28th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.72. The firm had revenue of $22.47 million for the quarter. Equities analysts predict that Dermira Inc will post ($3.70) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This story was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/04/21/insider-selling-dermira-inc-derm-insider-sells-83825-00-in-stock-updated.html.
Several institutional investors have recently modified their holdings of the company. Advisory Research Inc. purchased a new position in shares of Dermira during the fourth quarter worth approximately $1,447,000. BlackRock Fund Advisors increased its position in Dermira by 10.8% in the third quarter. BlackRock Fund Advisors now owns 1,325,981 shares of the biopharmaceutical company’s stock valued at $44,845,000 after buying an additional 129,437 shares in the last quarter. FMR LLC increased its position in Dermira by 10.1% in the fourth quarter. FMR LLC now owns 4,710,737 shares of the biopharmaceutical company’s stock valued at $142,877,000 after buying an additional 433,601 shares in the last quarter. Jana Partners LLC bought a new position in Dermira during the third quarter valued at about $5,055,000. Finally, Great Point Partners LLC bought a new position in Dermira during the third quarter valued at about $22,977,000. Hedge funds and other institutional investors own 84.92% of the company’s stock.
A number of equities research analysts have issued reports on the company. Mizuho assumed coverage on Dermira in a research report on Thursday, March 30th. They set a “buy” rating and a $42.00 price objective on the stock. Zacks Investment Research upgraded Dermira from a “sell” rating to a “hold” rating in a research report on Tuesday, January 10th. Guggenheim restated a “positive” rating and set a $40.00 price objective on shares of Dermira in a research report on Thursday, March 2nd. SEB Equity Research restated a “reduce” rating on shares of Dermira in a research report on Tuesday, January 3rd. Finally, Raymond James Financial, Inc. began coverage on Dermira in a research note on Thursday, March 16th. They set an “underperform” rating on the stock. Three analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $44.20.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc and related companies with MarketBeat.com's FREE daily email newsletter.